Mayo Clinic Laboratory and Pathology Research Roundup: February 10
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Impact of Minimal Residual Negativity using Next Generation Flow Cytometry on Outcomes in Light Chain Amyloidosis.
We evaluated bone marrow minimal residual disease (MRD) negativity in 44 patients with light chain (AL) amyloidosis using next generation flow cytometry (sensitivity > 1x 10-5 ; median events analyzed: 8.7 million, range: 4.8 to 9.7 million). All patients underwent MRD testing in two years from start of therapy (median: 7 months). Overall MRD negative rate was 64% (n=28). MRD-negative rate after one-line of therapy was 71% (20/28). MRD negative rates were higher with stem-cell transplant as first-line therapy (86%, 18/21) vs. chemotherapy alone as first-line treatment (29%, 2/7), p=0.005. MRD negative rate amongst patients in complete response were 75% (15/20); in very good partial response: 50% (11/22) and there were two patients in partial response/rising light chains (with renal dysfunction) who were MRD negative. There were no differences in baseline characteristics of MRD negative vs. MRD positive patients, except younger age among MRD-negative patients. MRD negative patients were more likely to have achieved cardiac response at the time of MRD assessment, 67% (8/12) vs. 22% (2/7), p=0.04. Renal response rates were similar in both groups. Progression free survival was assessed in the 42 patients achieving CR or VGPR. After median follow-up of 14 months, the estimated 1-year progression free survival in MRD negative vs. MRD positive patients was 100% (26 patients, 0 events) vs. 64% (16 patients, 5 events), p=0.006, respectively. MRD assessment should be explored as a surrogate endpoint in clinical trials and MRD risk-adapted trials may help optimize treatment in AL amyloidosis. This article is protected by copyright. All rights reserved. Via American Journal of Hematology.
Published to PubMed This Week
- Promise of Autologous CD34+ Stem/Progenitor Cell Therapy for Treatment of Cardiovascular Disease.
- Reply to On the Proportion of Male Breast Cancer Among all Breast Cancers.
- Pregnancy Outcomes in Myeloproliferative Neoplasms: A Mayo clinic Report on 102 Pregnancies.
American Journal of Hematology
- TDP-43 is Associated with a Reduced Likelihood of Rendering a Clinical Diagnosis of Dementia with Lewy Bodies in Autopsy-Confirmed Cases of Transitional/Diffuse Lewy Body Disease.
Journal of Neurology
- Antithrombotic Effects of Heme-Degrading and Heme-Binding Proteins.
American Journal of Physiology. Heart and Circulatory Physiology
- Predicting Chronic Subdural Hematoma Recurrence and Stroke Outcomes While Withholding Antiplatelet and Anticoagulant Agents.
Frontiers in Neurology
- Non-Aspergillus Hyaline Molds: Emerging Causes of Sino-Pulmonary Fungal Infections and Other Invasive Mycoses.
Seminars in Respiratory and Critical Care Medicine
- Update on Selected Advances in the Immunohistochemical and Molecular Genetic Analysis of Soft Tissue Tumors.
- What is New in Pericytomatous, Myoid, and Myofibroblastic Tumors?
- CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Clinical and Translations in Science
- Challenges with At-home and Mail-in Direct-to-Consumer Testing: Preanalytical Error, Reporting Results, and Result Interpretation.
Clinical Laboratory Medicine
- Celiac Disease Risk Stratification Based on HLA-DQ Heterodimer (HLA-DQA1 ~ DQB1) Typing in a Large Cohort of Adults with Suspected Celiac Disease.
- Multimodal Imaging and Histopathological Evaluation of Berger's Space.
Ocular Oncology and Pathology